Patents by Inventor Reuven Reich
Reuven Reich has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8993544Abstract: The present invention relates to novel metalloproteinase inhibitors having an aryloxybenzenesulfonamide moiety and a carbamoylphosphonic acid moiety, to pharmaceutical compositions comprising them, and to their uses in the prevention and/or treatment of disease or disorder associated with MMP.Type: GrantFiled: February 9, 2010Date of Patent: March 31, 2015Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd.Inventors: Eli Breuer, Reuven Reich, Julia Frant, Amnon Hoffman, Veerendhar Ainelly
-
Publication number: 20120035140Abstract: The present invention relates to novel metalloproteinase inhibitors having an aryloxybenzenesulfonamide moiety and a carbamoylphosphonic acid moiety, to pharmaceutical compositions comprising them, and to their uses in the prevention and/or treatment of disease or disorder associated with MMP.Type: ApplicationFiled: February 9, 2010Publication date: February 9, 2012Applicant: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, LTD.Inventors: Eli Breuer, Reuven Reich, Julia Frant, Amnon Hoffman, Veerendhar Ainelly
-
Patent number: 7468359Abstract: The present invention relates to compositions useful for treating or controlling disease states or conditions associated with zinc containing proteinases, especially metalloproteinases. The active ingredient in these compositions is an alpha-oxo- or alpha-thioxophosphonate of formula (I). Out of the phosphonates of formula (I), some are known and others are new. The novel compounds constitute another aspect of the invention.Type: GrantFiled: May 23, 2006Date of Patent: December 23, 2008Assignee: Yissum Research Develpment Company of the Hebrew University of JerusalemInventors: Eli Breuer, Reuven Reich, Claudio Salomon
-
Patent number: 7345033Abstract: The present invention provides a compound of the following formula I: R3—NH—C(?X)—P(?O)OR1OR2 including pharmaceutically acceptable salts, solvates, hydrates and polymorphs of the compounds of formula I, as well as geometrical isomers and optically active forms of the compounds of formula I and pharmaceutically acceptable salts, solvates, hydrates and polymorphs of said isomers and forms, wherein R1 and R2 may be the same or different and are each selected from hydrogen, acyloxyalkyl and aryl or R1 and R2 may form together with the oxygen and phosphorus atoms a dioxaphosphacycloalkane ring; X is O or S; and R3 is selected, when X is O, from bicycloalkyl, cycloalkylalkyl and substituted cycloalkyl by at least one of alkyl, amino, amidino and guanidino; and R3 is selected, when X is S, from bicycloalkyl, cycloalkylalkyl and cycloalkyl optionally substituted by at least one of alkyl, amino, amidino and guanidino; with the proviso that: when X is O, R3 is not cyclohexylmethyl, and when X is S, R3 is not cyclType: GrantFiled: October 6, 2005Date of Patent: March 18, 2008Assignee: Yissum Research Development Company of the Hebrew University of JerusalemInventors: Eli Breuer, Reuven Reich, Gershon Golomb, Yiffat Katz
-
Publication number: 20060199787Abstract: The present invention relates to compositions useful for treating or controlling disease states or conditions associated with zinc containing proteinases, especially metalloproteinases. The active ingredient in these compositions is an alpha-oxo- or alpha-thioxophosphonate of formula (I). Out of the phosphonates of formula (I), some are known and others are new. The novel compounds constitute another aspect of the invention.Type: ApplicationFiled: May 23, 2006Publication date: September 7, 2006Applicant: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEMInventors: Eli Breuer, Reuven Reich, Claudio Saloman
-
Patent number: 7101864Abstract: The present invention relates to compositions useful for treating or controlling disease states or conditions associated with zinc containing proteinases, especially metalloproteinases. The active ingredient in these compositions is an alpha-oxo- or alpha-thixophosphpnate of formula (I). Out of the phosphonates of formula (I), some are known and others are new. The novel compounds constitute another aspect of the invention.Type: GrantFiled: September 19, 2000Date of Patent: September 5, 2006Assignee: Yissum Research Development Company of the Hebrew University of JerusalemInventors: Eli Breuer, Reuven Reich, Claudio Salomon
-
Publication number: 20060111328Abstract: The present invention provides a compound of the following formula I: R3—NH—C(?X)—P(?O)OR1OR2 including pharmaceutically acceptable salts, solvates, hydrates and polymorphs of the compounds of formula I, as well as geometrical isomers and optically active forms of the compounds of formula I and pharmaceutically acceptable salts, solvates, hydrates and polymorphs of said isomers and forms, wherein R1 and R2 may be the same or different and are each selected from hydrogen, acyloxyalkyl and aryl or R1 and R2 may form together with the oxygen and phosphorus atoms a dioxaphosphacycloalkane ring; X is O or S; and R3 is selected, when X is O, from bicycloalkyl, cycloalkylalkyl and substituted cycloalkyl by at least one of alkyl, amino, amidino and guanidino; and R3 is selected, when X is S, from bicycloalkyl, cycloalkylalkyl and cycloalkyl optionally substituted by at least one of alkyl, amino, amidino and guanidino; with the proviso that: when X is O, R3 is not cyclohexylmethyl, and when X is S, R3 is not cType: ApplicationFiled: October 6, 2005Publication date: May 25, 2006Applicant: Yissum Research Development Company of the Hebrew University of JerusalemInventors: Eli Breuer, Reuven Reich, Gershon Golomb, Yiffat Katz
-
Patent number: 7034006Abstract: The invention provides novel methods for treating disease based upon the medicinal use of lipids and phospholipids covalently bound to physiologically acceptable monomers or polymers. Phosphatidylethanolamine moieties conjugated to physiologically acceptable monomers and polymers (PE conjugates) manifest an unexpectedly wide range of pharmacological effects, including stabilizing cell membranes; limiting oxidative damage to cell and blood components; limiting cell proliferation, cell extravasation and (tumor) cell migratory behavior; suppressing immune responses; and attenuating physiological reactions to stress, as expressed in elevated chemokine levels.Type: GrantFiled: January 10, 2001Date of Patent: April 25, 2006Assignee: Yissum Research Development Company of the Hebrew University of JerusalemInventors: Saul Yedgar, David Shuseyov, Gershon Golomb, Reuven Reich, Isaac Ginsburg, Abd-al-Roof Higazi, Moshe Ligumski, Miron Krimsky, David Ojcius, Benito Antonio Yard, Fokko Johannes van der Woude, Edit Schnitzer
-
Publication number: 20020049183Abstract: The invention provides novel methods for treating disease based upon the medicinal use of lipids and phospholipids covalently bound to physiologically acceptable monomers or polymers. Phosphatidylethanolamine moieties conjugated to physiologically acceptable monomers and polymers (PE conjugates) manifest an unexpectedly wide range of pharmacological effects, including stabilizing cell membranes; limiting oxidative damage to cell and blood components; limiting cell proliferation, cell extravasation and (tumor) cell migratory behavior; suppressing immune responses; and attenuating physiological reactions to stress, as expressed in elevated chemokine levels.Type: ApplicationFiled: January 10, 2001Publication date: April 25, 2002Inventors: Saul Yedgar, David Shuseyov, Gershon Golomb, Reuven Reich, Isaac Ginsburg, Abd-al-Roof Higazi, Moshe Ligumski, Miron Krimsky, David Ojcius, Benito Antonio Yard, Fokko Johannes van der Woude, Edit Schnitzer
-
Patent number: 5030642Abstract: The present invention relates to a method of inhibiting tumor metastasis in an aminal by administering to an animal in need of such treatment an acrylaminoalkylpryridineamides represented by the formula ##STR1## wherein: R.sub.1 and R.sub.2 are the same or different members of the group consisting of halo, phenyl, substituted phenyl and a ##STR2## group wherein n, m and p are independently an integer of from 1 to 8 provided n+m+p is equal to or less than 10; x is thio or sulfinyl; Alk.sub.1 is straight or branched chain lower alkylene of 1 to 6 carbon atoms, R.sub.3 is hydrogen or lower alkyl, Alk.sub.2 is straight or branched chain alkylene of 1 to 4 carbon atoms; R.sub.4 is selected from the group consisting of hydrogen, halo, hydroxy, lower alkyl and lower alkoxy; or a pharmaceutically acceptable salt thereof, in an amount effective to inhibit tumor metastasis.Type: GrantFiled: December 2, 1988Date of Patent: July 9, 1991Assignees: G. D. Searle & Co., The Government of the United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: George C. Fuller, George R. Martin, Richard A. Mueller, Reuven Reich
-
Patent number: 5010080Abstract: A method of inhibiting tumor metastasis in an animal without treating the tumor cells by administering to said animal a metastasis inhibiting effective amount of a heterocyclic amide represented by the formula: ##STR1## wherein: R.sub.1 and R.sub.2 are the same or different members of the group consisting of halo, phenyl, substituted phenyl and a ##STR2## group wherein q, r and t are independently an integer of from 1 to 8 provided that q+r+t is equal to or less than 10; Y is thio or sulfinyl; alk is straight or branched chain lower alkylene, and R.sub.3 is a heterocyclic amine represented by the formula: ##STR3## wherein R.sub.4 is selected from the group consisting of hydrogen, lower alkyl, phenyl, substituted phenyl, benzyl, or substituted benzyl; p is 0 to 2; or a pharmaceutically acceptable salt thereof.Type: GrantFiled: December 2, 1988Date of Patent: April 23, 1991Assignees: G. D. Searle & Co., The United States of America as represented by the Department of Health and Human ServicesInventors: George C. Fuller, George R. Martin, Richard A. Mueller, Reuven Reich